Vivodyne
Category: AI in Biotech / Drug Discovery
Frontier bio-AI lab generating causal human tissue data at scale to solve AI drug discovery's data gap, using robotic labs (HIVE) that grow, dose, and analyze thousands of lab-grown human tissues. Vivodyne was founded in 2020. The company is led by Andrei Georgescu. Based in San Francisco & Philadelphia, USA. Team size: 11-50. Total funding raised: $78M. Latest round: Series A. Key investors include Khosla Ventures, Kairos Ventures, CS Ventures, MBX Capital, Bison Ventures, Lingotto Investment Management, Helena Capital, Fortius Ventures.
- Founded
- 2020
- Headquarters
- San Francisco & Philadelphia, USA
- Team size
- 11-50
- Total funding
- $78M
Value proposition
Make biology computable by generating the causal, interventional human tissue data that AI drug-discovery models currently lack — replacing animal testing with realistic lab-grown human tissues tested at AI scale.
Products and solutions
HIVE robotic labs (autonomously cultivate, perturb, and analyze thousands of human tissues; 12-lab datacenter), TissueDisk Series 1 and Series 2 microfluidic chips (wafer-scale; hundreds of tissues per disk), self-assembling organ tissues (20+ types including liver, airway, bone marrow), causal phenomic/transcriptomic/proteomic data generation, human biological datacenters in San Francisco Bay Area and Philadelphia.
Unique value
Only company generating causal, interventional human tissue data at AI scale — 10,000 tissues per HIVE, 1-2 week data generation cycles, with claimed 94-100% concordance to real human organ behavior (liver, airway, bone marrow).
Target customer
Major biopharmaceutical companies (partners not publicly named) seeking to de-risk drug candidates before expensive clinical trials; AI drug-discovery model developers.
Industries served
Pharmaceutical drug discovery and development, preclinical toxicity testing, AI/ML foundation models for human biology.
Technology advantage
Proprietary microfluidic TissueDisk chips + autonomous HIVE robotic labs that generate causal (interventional) human tissue data at single-cell resolution — a data corpus built for training generalizable human tissue foundation models, with reinforcement-learning feedback loops.
How they differentiate
Unlike organ-on-chip competitors, Vivodyne combines AI-scale robotic automation (HIVE labs testing 10,000 tissues at once) with causal interventional data generation, positioning itself as a data-generation engine for AI drug discovery rather than just a tissue-testing platform.
Main competitors
Emulate, CN Bio, Hesperos, TissUse, MIMETAS
Key partnerships
Working with multiple major biopharma companies (unnamed publicly), spun out of University of Pennsylvania (Penn Center for Innovation), Pennovation Works alum.
Notable customers
Eight of the world's largest pharmaceutical companies have paid for early access (names not public).
Major milestones
2020: Founded at UPenn, 2021: Spun out of UPenn, Nov 2023: $38M seed led by Khosla Ventures, May 2025: $40M Series A led by Khosla Ventures, Aug 2026: Opened world's largest human data center near San Francisco.
Growth metrics
Claims 94% predictive accuracy for liver tissue vs human toxicity trials; 96% concordance for airway tissue; 100% concordance for bone marrow across 20 chemotherapy drugs; Aug 2026: launched 12-HIVE human biological datacenter (SF Bay Area & Philadelphia) with ~3.1M tissue experiments/year capacity.
Market positioning
Fast-scaling frontier bio-AI lab; claims world's largest human biological datacenter (12 HIVE labs; ~3.1M tissues/year) at roughly twice the scale of all U.S. clinical trials combined.
Geographic focus
US-centric (San Francisco & Philadelphia), with global biopharma partnerships.
Patents and IP
Vivodyne has been awarded multiple patents (per Penn Center for Innovation).
About Andrei Georgescu
PhD in Bioengineering, University of Pennsylvania; worked in Dan Huh's lab at Penn before co-founding Vivodyne in 2020.
Latest news about Vivodyne
More AI in Biotech / Drug Discovery companies
Official website: https://www.vivodyne.com